Evidence map›Paper›PMID 39194205›Full record

ArticleAntimicrobial agents and chemotherapy2024

Adjuvants restore colistin sensitivity in mouse models of highly colistin-resistant isolates, limiting bacterial proliferation and dissemination.

Beverly H Koller, Leigh A Jania, Haoting Li, William T Barker, Roberta J Melander, Christian Melander

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Beverly H KollerDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-1433-359X
Leigh A JaniaDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Haoting LiDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
William T BarkerDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
Roberta J MelanderDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.ORCID 0000-0002-3548-3351
Christian MelanderDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.ORCID 0000-0001-8271-4696

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Systematic in vivo characterization of disease-associated regulatory variantsUM1HG012003 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael Isaiah Love, KAREN L. MOHLKE · 2021 to 2026
$9.9M
Colistin-resistant Acinetobacter baumanniiR01AI104895 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI, ERNST, ROBERT K · 2014 to 2024
$4.2M
Development of Antibiotic Adjuvants for Gram-Negative BacteriaR01AI136904 · NIAID · UNIVERSITY OF NOTRE DAME · PI MELANDER, CHRISTIAN COREY · 2018 to 2022
$3.7M
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic AdjuvantsR01AI167284 · NIAID · UNIVERSITY OF NOTRE DAME · PI MELANDER, CHRISTIAN COREY · 2022 to 2025
$3.7M
HHS | National Institutes of Health (NIH) R01AI136904, R01AI167284NCI NIH HHS P30 CA016086NHGRI NIH HHS UM1 HG012003NIAID NIH HHS R01 AI104895NIAID NIH HHS R01 AI136904NIAID NIH HHS R01 AI167284
6 · The paper itself

Abstract

Antimicrobial resistance (AMR) has led to a marked reduction in the effectiveness of many antibiotics, representing a substantial and escalating concern for global health. Particularly alarming is resistance in Gram-negative bacteria due to the scarcity of therapeutic options for treating infections caused by these pathogens. This challenge is further compounded by the rising incidence of resistance to colistin, an antibiotic traditionally considered a last resort for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. In this study, we demonstrate that adjuvants restore colistin sensitivity

Indexed as

Anti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialMicrobial Sensitivity TestsAcinetobacter baumanniiAdjuvants, PharmaceuticAnimalsBenzamidesBenzimidazolesDisease Models, AnimalFemaleHumansKlebsiella pneumoniaeMiceAdjuvants, PharmaceuticAnti-Bacterial AgentsBenzamidesBenzimidazolesColistinN-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamideAcinetobacter baumanniiadjuvantcolistinKlebsiella pneumoniae

Identifiers

PMID39194205
PMCPMC11459950

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.